SEC Comment Letter 0000000000-25-006066 to Inozyme Pharma, Inc. (CIK 0001693011)
Inozyme Pharma, Inc. (CIK 0001693011)
Date: June 9, 2025 · CIK: 0001693011 · Accession: 0000000000-25-006066
AI Filing Summary & Sentiment
Letter
June 9, 2025 Jamie Leigh Partner Cooley LLP 3 Embarcadero Center 20th Floor San Francisco, CA 94111-4004 Re:Inozyme Pharma, Inc. SC TO-T filed June 2, 2025, amended June 4, 2025 Filed by Incline Merger Sub, Inc. and Biomarin Pharmaceutical Inc. File No. 005-91586 Dear Jamie Leigh: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Schedule TO-T Offer to Purchase - Background of the Offer, page 28 1.Please revise your disclosure to describe the preliminary discussions Parent carried out in 2024 with Inozyme, including the individuals involved and the setting of such discussions. 2.Describe the negotiations of the tender and support agreements. In addition, disclose the name of the shareholders with whom you negotiated the agreements and, if different, those with whom you entered into agreement. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
June 9, 2025 Page 2 Please direct any questions to Daniel Duchovny at 202-551-3619. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
June 9, 2025
Jamie Leigh
Partner
Cooley LLP
3 Embarcadero Center
20th Floor
San Francisco, CA 94111-4004
Re:Inozyme Pharma, Inc.
SC TO-T filed June 2, 2025, amended June 4, 2025
Filed by Incline Merger Sub, Inc. and Biomarin Pharmaceutical Inc.
File No. 005-91586
Dear Jamie Leigh:
We have reviewed your filing and have the following comments. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to these comments by providing the requested information or advise us
as soon as possible when you will respond. If you do not believe our comments apply to your
facts and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
Schedule TO-T
Offer to Purchase - Background of the Offer, page 28
1.Please revise your disclosure to describe the preliminary discussions Parent carried
out in 2024 with Inozyme, including the individuals involved and the setting of such
discussions.
2.Describe the negotiations of the tender and support agreements. In addition, disclose
the name of the shareholders with whom you negotiated the agreements and, if
different, those with whom you entered into agreement.
We remind you that the filing persons are responsible for the accuracy and adequacy
of their disclosures, notwithstanding any review, comments, action or absence of action by
the staff.
June 9, 2025
Page 2
Please direct any questions to Daniel Duchovny at 202-551-3619.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions